Enochian Biosciences Inc. (ENOB)
NASDAQ: ENOB
· Real-Time Price · USD
0.71
0.01 (1.43%)
At close: Aug 04, 2023, 9:58 PM
Enochian Biosciences Cash Flow Statement
Financials in USD. Fiscal
year is
July - June.
| Fiscal Year | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q2 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Dec 31, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 |
Net Income | 39,683.9B | 39,683.9B | -120.53M | -80.65M | -39,684B | -39,684.1B | -106.72M | -108.6M | -110.72M | -113.43M | -40.56M | -38.39M | -34.74M | -26.72M | -13.46M | -10.94M | -9.73M |
Depreciation & Amortization | -113.5B | -113.5B | 126K | 121.86K | 113.5B | 113.5B | 113.82K | 117.3K | 120.26K | 123.59K | 394.63K | 393.74K | 392.69K | 391.42K | 121.71K | 119.08K | 117.56K |
Stock-Based Compensation | -3,535B | -3,535B | 3.95M | 4.67M | 3,535B | 3,535.1B | 3.06M | 2.57M | 3.79M | 5.49M | 5.61M | 5.53M | 3.85M | 1.44M | 1.32M | 790.2K | 1.12M |
Other Working Capital | 3,895B | 3,895B | 74.69K | n/a | -3,895B | -3,895B | 1.18M | 1.52M | 1.2M | 333.8K | 401.44K | -32.71K | 502.91K | 1.2M | 316.24K | 708.98K | -219.76K |
Other Non-Cash Items | -24,260.9B | -24,260.9B | 64.81M | 64.88M | 24,261B | 24,261B | 85.81M | 87.96M | 88.2M | 90.67M | 8.46M | 7.26M | 6.6M | 3.34M | 1.7M | -1.58M | -2.38M |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -68.66K | n/a | -199.91K | -132.61K | 2.68K | n/a | 59.91K | -7.39K | -142.88K |
Change in Working Capital | -1.53M | 1.46M | 158.56K | n/a | -3.33M | n/a | 5.17M | 5.91M | 5.34M | 1.42M | 383.6K | -54.89K | 768.4K | 932.13K | 492.74K | 273.61K | -541.97K |
Operating Cash Flow | 11,774.5B | 11,774.5B | -9.68M | -10.97M | -11,774.5B | -11,774.5B | -12.56M | -12.04M | -13.28M | -15.73M | -25.71M | -25.26M | -23.13M | -20.61M | -9.83M | -11.34M | -11.41M |
Capital Expenditures | 29.77B | 29.77B | -70.43K | -70.43K | -29.77B | -29.77B | -23.63K | -23.63K | n/a | -5.16K | -43.33K | -43.33K | -54.05K | -48.89K | -21.17K | -62.86K | -115.85K |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Sales Maturities Of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Investing Acitivies | -2.65M | -1.19M | -1.19M | -1.19M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Investing Cash Flow | 29.77B | 29.77B | -1.26M | -1.26M | -29.77B | -29.77B | -23.63K | -23.63K | n/a | -5.16K | -43.33K | -43.33K | -54.05K | -48.89K | -21.17K | -62.86K | -115.85K |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | -3,315B | -3,315B | 1,200B | 1,200B | 4,515.1B | 4,515.1B | 4,250.5B | 4,250.5B | 4,250.5B | 4,250.5B | 32.38M | 35.59M | 32.6M | 32.6M | 3.4M | 6.16M | 6.2M |
Financial Cash Flow | -4,515B | -4,515B | 10.44M | 10.52M | 4,515.1B | 4,515.1B | 4.34M | 2.46M | 5.88M | 4.25M | 32.38M | 35.59M | 32.6M | 32.6M | 3.4M | 6.16M | 6.2M |
Net Cash Flow | 702.53K | 91.3K | 1,874.5B | 1,874.5B | 1,874.5B | 1,874.5B | -8.2M | -9.59M | -7.41M | -11.49M | 6.62M | 10.28M | 9.41M | 11.97M | -6.41M | -5.2M | -5.17M |
Free Cash Flow | 11,804.3B | 11,804.3B | -9.75M | -11.04M | -11,804.3B | -11,804.3B | -12.59M | -12.06M | -13.28M | -15.74M | -25.75M | -25.3M | -23.19M | -20.66M | -9.85M | -11.4M | -11.53M |